Evidence map›Paper›PMID 41053536›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1.

Linyi Hu, Guigen Zhang, Yuan Lin, Shiming Yi, Jingyu Yang, Xueying Lin, Deli Song, Zhiheng Liu, Jiayu Zhang, Ying Zeng and 11 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Linyi HuDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Guigen ZhangDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Yuan LinGuangmei Yan, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Shiming YiDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Jingyu YangGuangmei Yan, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Xueying LinDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Deli SongSchool of Life Sciences, Peking University, Beijing, 100871, China.
Zhiheng LiuSchool of Life Sciences, Peking University, Beijing, 100871, China.
Jiayu ZhangThe Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, China.
Ying ZengDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Shanyu HuangGuangmei Yan, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Zhen FanDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Jifu ZhangDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Ying LiuThe Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
Cheng HuThe Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
Wenbo ZhuGuangmei Yan, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Wei YinDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Jun HuDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Guangmei YanGuangmei Yan, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Jing CaiDepartment of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Jiankai LiangDepartment of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.ORCID https://orcid.org/0000-0002-4378-7646

Funding

Guangdong Basic and Applied Basic Research Foundation 2022B1515020056Guangdong Basic and Applied Basic Research Foundation 2024A1515010317National Key R&D Program of China 2021YFA0909800National Natural Science Foundation of China 82204447National Natural Science Foundation of China 82373285National Natural Science Foundation of China 82473324Science and Technology Project of Guangzhou City 2023A03J0200
6 · The paper itself

Abstract

Viral receptors are essential host factors that determine the tropism of oncolytic viruses, and contribute to their selective targeting of cancer cells. In this study, a membrane protein-targeted CRISPR-Cas9 screen is conducted and identify transmembrane protein adipocyte-associated 1 (TPRA1) as a novel receptor for oncolytic virus M1(OVM), a promising oncolytic virus currently under clinical investigation. Mechanistically, TPRA1 facilitates OVM infection by promoting both viral attachment and internalization. Extracellular region of TPRA1 directly binds OVM particles via glycosylation, while its cytoplasmic tail mediates virus endocytosis, collectively enabling efficient viral entry and cancer cell lysis. Importantly, TPRA1 expression in cell lines, mouse models, and patient-derived tumor samples are positively correlated with their respective sensitivity to OVM, and TPRA1 is upregulated in a high proportion of tumors compared to adjacent normal tissues, highlighting its potential as a therapeutic response biomarker. Furthermore, TPRA1 also promotes the entry of Semliki Forest Virus, suggesting its conserved role in alphavirus infection. Together, these findings establish TPRA1 as both a mechanistic determinant of OVM tropism and a biomarker to guide patient selection in clinical trials of OVM-based therapy.

Indexed as

Oncolytic VirotherapyOncolytic VirusesReceptors, VirusAnimalsBiomarkersCell Line, TumorHumansMiceNeoplasmsVirus InternalizationBiomarkersReceptors, Virusbiomarkeroncolytic virus M1receptorTPRA1viral entry

Identifiers

PMID41053536
PMCPMC12752648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.